The 36-month beta value for ARWR is at 0.93. Analysts have varying views on the stock, with 7 analysts rating it as a “buy,” 3 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for ARWR is 114.47M, and currently, shorts hold a 8.03% of that float. The average trading volume for ARWR on March 20, 2025 was 1.88M shares.
ARWR) stock’s latest price update
The stock price of Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has surged by 2.48 when compared to previous closing price of 15.10, but the company has seen a -1.90% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-03-10 that PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to present additional results at a medical meeting in 2025. Select Phase 1/2 Study Results Patients with IgA nephrop.
ARWR’s Market Performance
Arrowhead Pharmaceuticals Inc (ARWR) has experienced a -1.90% fall in stock performance for the past week, with a -24.32% drop in the past month, and a -29.20% drop in the past quarter. The volatility ratio for the week is 4.63%, and the volatility levels for the past 30 days are at 5.99% for ARWR. The simple moving average for the last 20 days is -10.52% for ARWR stock, with a simple moving average of -29.05% for the last 200 days.
Analysts’ Opinion of ARWR
Many brokerage firms have already submitted their reports for ARWR stocks, with Goldman repeating the rating for ARWR by listing it as a “Neutral.” The predicted price for ARWR in the upcoming period, according to Goldman is $31 based on the research report published on June 05, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see ARWR reach a price target of $29. The rating they have provided for ARWR stocks is “Buy” according to the report published on December 04th, 2023.
Citigroup gave a rating of “Neutral” to ARWR, setting the target price at $33 in the report published on September 19th of the previous year.
ARWR Trading at -17.46% from the 50-Day Moving Average
After a stumble in the market that brought ARWR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.13% of loss for the given period.
Volatility was left at 5.99%, however, over the last 30 days, the volatility rate increased by 4.63%, as shares sank -26.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.83% lower at present.
During the last 5 trading sessions, ARWR fell by -1.90%, which changed the moving average for the period of 200-days by -32.09% in comparison to the 20-day moving average, which settled at $17.29. In addition, Arrowhead Pharmaceuticals Inc saw -17.71% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARWR starting from Anzalone Christopher Richard, who sale 51,425 shares at the price of $15.07 back on Mar 13 ’25. After this action, Anzalone Christopher Richard now owns 4,062,377 shares of Arrowhead Pharmaceuticals Inc, valued at $774,975 using the latest closing price.
Anzalone Christopher Richard, the Officer of Arrowhead Pharmaceuticals Inc, proposed sale 51,425 shares at $15.07 during a trade that took place back on Mar 13 ’25, which means that Anzalone Christopher Richard is holding shares at $774,785 based on the most recent closing price.
Stock Fundamentals for ARWR
Current profitability levels for the company are sitting at:
- -250.38 for the present operating margin
- -2.72 for the gross margin
The net margin for Arrowhead Pharmaceuticals Inc stands at -255.89. The total capital return value is set at -0.68. Equity return is now at value -600.68, with -78.01 for asset returns.
Based on Arrowhead Pharmaceuticals Inc (ARWR), the company’s capital structure generated 0.69 points at debt to capital in total, while cash flow to debt ratio is standing at -4.24. The debt to equity ratio resting at 2.2. The interest coverage ratio of the stock is -12.87.
Currently, EBITDA for the company is -561.51 million with net debt to EBITDA at -0.11. When we switch over and look at the enterprise to sales, we see a ratio of 874.5. The receivables turnover for the company is 1.0for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.09.
Conclusion
In conclusion, Arrowhead Pharmaceuticals Inc (ARWR) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
